Cytosorbents Earnings Call Balances Progress and Pressure

Cytosorbents Corp ((CTSO)) has held its Q1 earnings call. Read on for the main highlights of the call.

Cytosorbents’ latest earnings call struck a tone of cautious optimism, as management highlighted modest revenue growth, solid international momentum, and strong margins against a backdrop of FX-driven losses, regulatory delays, and tight liquidity. Executives stressed disciplined cost control and a clear regulatory roadmap while acknowledging that U.S. approval and cash flow breakeven remain medium‑term goals rather than near‑term milestones.

Top Line Holds Up Amid Currency and Market Headwinds

Cytosorbents reported Q1 2026 revenue of $8.9 million, up 2% year over year despite a 7% decline on a constant currency basis, underscoring resilience in a challenging macro and regulatory environment. Management framed the quarter as a proof point that core demand is stable even as FX and regional softness, particularly in Germany, weigh on reported growth.

International Direct Business Drives Growth Outside Germany

Direct international sales outside Germany grew 13% year over year, signaling rising physician awareness and stronger execution in key hospitals. The company is leaning on these geographies to offset German weakness, suggesting that these markets are becoming the primary engine for near‑term revenue expansion.

Large Installed Base Supports Recurring Revenue Model

Core CytoSorb product sales exceeded $37 million in 2025, with more than 300,000 devices used across over 70 countries, reinforcing a sizable installed base. Management emphasized the razor‑and‑blade dynamic, where recurring cartridge use on existing platforms offers a durable revenue stream once adoption is established.

Adjusted Profitability Metrics Trend in the Right Direction

The adjusted net loss narrowed to $3.4 million, or $0.05 per share, from $3.7 million, while adjusted EBITDA loss improved to $2.2 million from $2.7 million. These improvements reflect early benefits from restructuring and cost discipline, even as GAAP results remain pressured by noncash FX effects.

Cost Cuts and Lower Cash Burn Ease Pressure

Operating expenses fell to $9.2 million from $10.1 million year over year, aided by a roughly 10% headcount reduction executed in late 2025. Total cash burn improved to about $1.1 million in the quarter, excluding $300,000 of restructuring payments, underscoring progress toward a leaner operating model.

Healthy Margins and Tighter Working Capital Management

Gross margin remained robust at 69%, only modestly below the prior year’s 71% despite deliberate production cuts. Management said it slowed manufacturing to reduce inventory to $4.8 million from $5.3 million, prioritizing working capital efficiency even at the cost of a slight near‑term margin drag.

DrugSorb‑ATR Pipeline Backed by Strong Clinical Evidence

The STAR‑T randomized trial, published in a leading cardiac surgery journal, showed more than a 50% reduction in severe bleeding when removing ticagrelor with DrugSorb‑ATR. The device maintains two FDA Breakthrough designations, and the agency has provided clear guidance that real‑world evidence plus mechanistic data can support a defined regulatory path.

New Devices Boost Adoption and Procedural Integration

Cytosorbents has placed more than 100 PuriFi pumps internationally and launched the HotSwap device, both designed to improve ease of use and dosing strategies. Early feedback has been positive, and management believes these tools will deepen penetration in critical care and cardiac surgery settings by simplifying workflow for clinicians.

Roadmap to Operating Cash Flow Breakeven in 2026

The company reiterated its target of achieving operating cash flow breakeven in the second half of 2026, leaning on lower operating expenses and operational efficiencies. Investors are being asked to look through near‑term volatility and focus on a cost base that management believes is now better aligned with revenue.

GAAP Net Loss Widened by Foreign Exchange Volatility

GAAP net loss increased to $5.1 million, or $0.08 per share, from $1.5 million, largely driven by noncash foreign currency transaction impacts. While this headline number may unsettle some investors, management argued that underlying trends are better captured in the improved adjusted loss metrics.

Declining Cash Balance Highlights Liquidity Constraints

Total cash, cash equivalents, and restricted cash fell to about $6.4 million as of March 31, 2026, down from $7.8 million at year‑end, leaving limited short‑term headroom. With cash burn still positive, the company’s ability to fund additional studies and regulatory work without new capital remains a key risk for shareholders to monitor.

FDA De Novo Delay Extends U.S. Approval Timeline

The FDA upheld its prior de novo denial and requested additional mechanistic, nonclinical data alongside real‑world evidence, pushing a new submission into late 2026 or early 2027. This delay requires incremental investment in studies and effectively shifts any meaningful U.S. revenue contribution from DrugSorb‑ATR further into the back half of the decade.

Restructuring German Operations Amid Market Weakness

Direct sales in Germany declined year over year, prompting Cytosorbents to shrink and restructure its local sales force to better match current demand. Management plans to selectively rebuild the team as conditions stabilize, but near‑term growth from this historically important market is likely to remain subdued.

Geopolitical Tensions Disrupt Distributor Channels

Distributor sales were essentially flat, weighed down by geopolitical disruptions linked to conflict in the Middle East, which delayed roughly $0.5 million of expected orders. The impact was most notable in the company’s Dubai subsidiary and some EMEA markets, highlighting the geographic risk inherent in its distributor model.

Margin Impact from Intentional Production Slowdown

Gross margin slipped by 2 percentage points to 69% as reduced production volumes spread fixed costs over fewer units, a trade‑off management accepted to right‑size inventory. Executives guided that margins are likely to stay in the high‑60s to low‑70s range near term, balancing profitability with working capital discipline.

Guidance Emphasizes Discipline, Regulatory Milestones, and U.S. Upside

Management reaffirmed its 2026 operating cash flow breakeven goal and highlighted ongoing cost reductions, including prior headcount cuts, as key levers. On the regulatory side, a DrugSorb‑ATR de novo filing is now expected in late 2026 or early 2027 with a typical 150‑day review, a DOAC pre‑submission is planned shortly, and the company is sizing the potential U.S. opportunity for DrugSorb‑ATR in the mid‑hundreds of millions of dollars.

Cytosorbents’ earnings call painted a picture of a company tightening its belt, leaning on international demand, and methodically pushing a high‑value pipeline through a slower‑than‑hoped U.S. approval process. While FX noise, cash constraints, and regulatory delays pose real risks, investors heard a management team focused on execution, margin resilience, and a credible path to cash flow breakeven over the next two years.